Arctoris and Evariste Technologies Form Joint Venture to Identify Novel Small Molecule cMET Inhibitors for Non-Small Cell Lung Cancer

0

Overview

  • Post by :
  • Source: Arctori
  • Dated: March 07, 2022

March 07, 2022, Oxford and London – Life Science Newswire – Arctoris, a technology-driven biopharmaceutical company, and Evariste Technologies, an AI drug discovery company, today announced that they have formed a joint venture to identify novel kinase inhibitors molecules for the treatment of patients with non-small cell lung cancer (NSCLC).

Current treatment options for NSCLC are limited, especially in the advanced stages. The cMet proto-oncogene has been shown to be mutated or upregulated in approximately 5% of all NSCLC cases. Although cMET has been successfully targeted by two recently approved drugs (tepotinib, capmatinib), rapid development of resistance has been reported and there is a clear need for improved second-generation cMET inhibitors to overcome resistance.

Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC). The partnership brings together two highly synergistic approaches to designing molecules guided by AI and robotics, to significantly accelerate the DMTA (Design, Make, Test, Analyze) cycle.

The two companies are combining their AI- and robotics-guided drug discovery platforms to develop a set of novel kinase inhibitors against cMET. The partnership will bring together two highly synergistic approaches – quantitative decision-making and cutting-edge generative chemistry, combined with real-time biological and biochemical profiling and data generation, to dramatically accelerate the design-make-test-analyze cycle. Both companies will also use their close ties to leading NSCLC treatment centers to leverage clinical knowledge, inform their discovery and development efforts, and directly address clinically relevant liabilities limiting the effectiveness of currently available therapies.

“We are really excited to work with Arctoris on this project. There is a huge need for next-generation cMET inhibitors for NSCLC. This is a cancer that affects millions of people around the world, and we hope we can bring significant benefits to some of those lives in the near future,” shares Dr. Nicholas Firth, CEO of Evariste Technologies .

Arctoris CEO, Martin-Immanuel Bittner, MD DPhil FRSA, commented on the joint venture: “With our partners at Evariste, we are developing new treatment options in NSCLC against a fully validated target, where first-generation inhibitors can be clinically meaningfully improved. . By combining patient-provided insights into resistance and toxicity patterns with AI-powered molecule design and our robotic platform, Ulysses, we aim to develop superior next-generation inhibitors in a dramatically accelerated timeframe. .

The collaboration between Arctoris and Evariste is already underway and has identified a new active chemical material. “We look forward to keeping our community informed of the progress we are making within the joint venture between Evariste Technologies and Arctoris. We are already off to an amazing start and we look forward to continuing our work to develop better treatment options for patients around the world,” shares Bittner.

About Arctoris, Ltd
Arctoris is a drug discovery technology company based in Oxford and Boston. Arctoris combines its unique automation platform, Ulysses, with advanced computational approaches and a world-class team of seasoned drug hunters to guide and rapidly advance its wholly-owned oncology and neurology drug discovery programs and in partnership.

Share.

About Author

Comments are closed.